Articles related to PARKINSON'S DISEASE (PD)

Multiple studies’ pooled data revealed a significantly increased risk of Parkinson’s when combined with bullous pemphigoid, a rare skin condition, inflammatory bowel disease (IBD), or Sjögren’s syndrome. Immune response impairment has been linked to Parkinson’s disease in a growing body of evidence. Indeed, some studies have suggested that the neurodegenerative disease may be exacerbated by autoimmune processes, which occur when the immune system incorrectly attacks and destroys healthy tissue.

Per Svenningsson, MD, PhD, a neurologist with expertise in Parkinson’s disease, will serve as the multicenter trial’s principal investigator. He previously oversaw a clinical study using montelukast (Singulair) tablets to treat PD. The multicenter trial is anticipated to begin between July and September. During the 18-month trial, participants will be randomized to receive either montelukast VersaFilm or a placebo film. IntelGenx plans to use the results to enhance the clinical development of its montelukast VersaFilm for Parkinson’s.

The evidence for NAD supplement effectiveness at present comes only from animal models and very small-scale human studies. And some studies link excessive consumption of NADH to anxiety and insomnia, and NAD precursors to Parkinson’s disease and diabetes.

Questions run across a host of topics, and in September you can challenge yourself in mortality risk, myocardial infarction (MI), insomnia, liver cancer, lipids, and Parkinson’s disease guidelines. Each question is worth 4 points with bonuses for quick response. Speed matters in this quiz. Why not give it a try and see if you can get on the leaderboard of the Smartest Doc?

Hear, watch, or read the top-line observations from a Harris Poll that included more than 360 patients and 120 caregivers on the impact of symptomatic neurogenic orthostatic hypotension (nOH). Suffice, many described severe limitations to their ability to perform activities that are necessary for day-to-day living.